Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A factor X analog which contains a modification ~~between~~ in the region of amino acid residues Glu226 to Ile235 ~~Glu226 and Ile235~~ of SEQ ID NO:2, such that amino acids Glu226 to Arg234 and ~~residue~~ amino acid 235 of SEQ ID NO:2 have the sequence Glu226-R8-R7-R6-R5-R4-R3-R2-Arg234-R1, wherein

a) R1 is Ile, Val, or Ala;

b) R2 is Thr, Ser, or Asn;

c) R3 is Phe, Leu, Arg, or Ile;

d) R4 is Asp, Lys, Thr, or Glu;

e) R5 is Asn, Ser, Lys, Met, Thr, or Asp;

f) R6 is Phe, Thr, Ser, Pro, Leu, or Ile;

g) R7 is Ser, Gln, Ile, Thr, Asn, or Pro; and

h) R8 is Gln, Ser, His, Tyr, or Glu.

2-3. (canceled)

4. (previously presented) The factor X analog of claim 1, wherein the amino acid sequence of residues 227-233 (R8-R7-R6-R5-R4-R3-R2) is Gln227-Ser228-Phe229-Asn230-Asp231-Phe232- Thr233 (SEQ ID NO:17).

5. (canceled)

6. (currently amended) The factor X analog of claim 1, wherein the amino acid sequence ~~from~~ of residues 227-233 (R8-R7-R6-R5-R4-R3-R2) is Ser 227-Gln228-Thr229-Ser230-Lys231-Leu232 (SEQ ID NO:18).

7. (canceled)

8. (previously presented) The factor X analog of claim 1, wherein the modification forms a processing site for factor XIa or a derivative thereof.

9. (currently amended) A factor X analog comprising a factor X sequence which contains (1) a modification in the region of amino acid residues Glu226 to Ile235 of SEQ ID NO:2, such that amino acids Glu226 to Arg234 and amino acid 235 of SEQ ID NO:2 have the sequence Glu226-R8-R7-R6-R5-R4-R3-R2-Arg234-R1, and (2) an additional modification in a C-terminal region of the factor X sequence, and wherein

a) R1 is Ile, Val, or Ala;
b) R2 is Thr, Ser, or Asn;
c) R3 is Phe, Leu, Arg, or Ile;
d) R4 is Asp, Lys, Thr, or Glu;
e) R5 is Asn, Ser, Lys, Met, Thr, or Asp;
f) R6 is Phe, Thr, Ser, Pro, Leu, or Ile;
g) R7 is Ser, Gln, Ile, Thr, Asn, or Pro;
h) R8 is Gln, Ser, His, Tyr, or Glu.

~~The factor X analog of claim 1, further comprising an additional modification in the region of the C-terminal factor X amino acid sequence.~~

10. (previously presented) The factor X analog of claim 9, wherein the additional modification is in the C-terminal region of the ß-peptide cleavage site.

11. (previously presented) The factor X analog of claim 1, wherein said modification permits an *in vivo* activation of the factor X analog into native factor Xa or a factor Xa analog.

12. (previously presented) The factor X analog of claim 1, wherein said modification permits an *in vitro* activation of the factor X analog into native factor Xa or a factor Xa analog.

13. (currently amended) The factor X analog of claim 1~~, wherein said analog~~ that contains an intact ß-peptide.

14. (previously presented) The factor X analog of claim 1 which is in the form of a double-chain molecule.

15. (original) The factor X analog of claim 1 having a shortened C-terminal region.

16. (canceled)

17. (previously presented) A preparation comprising the factor X analog of claim 1 or a precursor protein thereof.

18. (previously presented) The preparation of claim 17, wherein the modification is between Glu226 and Arg234 of SEQ ID NO:2.

19. (currently amended) The preparation ~~as claimed in~~ of claim 17, wherein the modification forms a cleavage site for factor XIa or a derivative thereof.

20. (previously presented) The preparation of claim 17, wherein the factor X analog is a FXα analog.

21. (previously presented) The preparation of claim 17, wherein the factor X analog has a shortened C-terminal amino acid sequence.

22. (previously presented) The preparation of claim 17, wherein the factor X analog is a double-chain molecule.

23. (previously presented) The preparation of claim 17, wherein

the factor X analog is a single-chain factor X analog in enzymatically inactive form that is at least 80% pure; and

the preparation does not contain inactive proteolytic intermediates of factor X/Xa analog.

24. (previously presented) The preparation of claim 17, wherein the factor X analog is a single-chain molecule.

25. (previously presented) The preparation of claim 17, wherein the modification permits an *in vivo* activation of the factor X analog into native factor Xa or a factor Xa analog.

26. (previously presented) The preparation of claim 17, wherein the modification permits an *in vitro* activation of the factor X analog into native factor Xa or into a factor Xa analog.

27. (previously presented) The preparation of claim 17 that is formulated as a pharmaceutical preparation.

28. (previously presented) A method for obtaining a preparation comprising an activated factor X analog, the method comprising:

(a) providing the factor X analog of claim 1; and

(b) activating the factor X analog to obtain the activated factor X analog.

29. (previously presented) The method of claim 28, further comprising formulating the preparation with a physiologically acceptable matrix.

30. (previously presented) The method of claim 28, further comprising combining the preparation with a blood factor or an activated form of a blood factor as an additional component.

31. (previously presented) The method of claim 30, wherein the additional component comprises at least one component with factor VIII inhibitory bypass activity.

32. (previously presented) The preparation of claim 17 that is formulated as a pharmaceutical compound and present as a multi-component preparation.

33. (previously presented) A method for preparing a pharmaceutical composition, comprising formulating the preparation of claim 17 as pharmaceutical composition.

34-43. (canceled)